Condition
Platinum-Resistant Primary Peritoneal Carcinoma clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Platinum-Resistant Primary Peritoneal Carcinoma clinical trials that are recruiting, at sites in 3 countries (most in United States (4), Canada (1), South Korea (1)). By phase: Phase 2 (3), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 3Countries
Newest Platinum-Resistant Primary Peritoneal Carcinoma clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Lorigerlimab for advanced platinum‑resistant and clear‑cell gynecologic cancers | Phase 2 | Los Angeles, California and 15 other locations | Recruiting | Dec 12, 2024 |
| Using MUC1-activated T cells to treat resistant ovarian cancer | Phase 1 | Scottsdale, Arizona | Recruiting | Jul 1, 2024 |
| Combining vismodegib and atezolizumab for treating resistant ovarian cancer | Phase 2 | Pittsburgh, Pennsylvania | Recruiting | Sep 13, 2022 |
| Combining ONC201 with Paclitaxel for Ovarian Cancer Treatment | Phase 2 | Detroit, Michigan and 1 other locations | Recruiting | Aug 14, 2019 |
All recruiting trials (4)
-
Lorigerlimab for advanced platinum‑resistant and clear‑cell gynecologic cancers
This trial will test lorigerlimab given by IV every three weeks in people with platinum‑resistant ovarian, fallopian tube, primary peritoneal, or clear‑cell gynecologic cancers.
-
Using MUC1-activated T cells to treat resistant ovarian cancer
This study is testing a new treatment using specially designed immune cells to see if they can help people with tough-to-treat ovarian cancer feel better and improve their health.
-
Combining vismodegib and atezolizumab for treating resistant ovarian cancer
This study is testing a new combination of two drugs, vismodegib and atezolizumab, to see if they can help people with ovarian cancer that hasn't responded to standard treatments.
-
Combining ONC201 with Paclitaxel for Ovarian Cancer Treatment
This study is testing if combining a new drug called ONC201 with paclitaxel can help people with hard-to-treat ovarian cancer feel better and live longer.
Related topics
Quick answers
How many Platinum-Resistant Primary Peritoneal Carcinoma clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 3 countries. The most sites are in United States (4 trials), Canada (1 trial), South Korea (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 3, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.